key: cord-0866797-u6eont9l
authors: Herrmann, Lars; Hahn, Friedrich; Wangen, Christina; Marschall, Manfred; Tsogoeva, Svetlana B.
title: Anti‐SARS‐CoV‐2 Inhibitory Profile of New Quinoline Compounds in Cell Culture‐Based Infection Models
date: 2022-01-18
journal: Chemistry
DOI: 10.1002/chem.202200039
sha: 32e8132fbf1bef925c6f2138fd6fcf27011f9d5b
doc_id: 866797
cord_uid: u6eont9l

Invited for the cover of this issue are Manfred Marschall, Svetlana B. Tsogoeva and co‐workers at Friedrich‐Alexander University of Erlangen–Nürnberg. The image depicts a new anti‐SARS‐CoV‐2 compound in front of SARS‐CoV‐2 viruses. Read the full text of the article at 10.1002/chem.202103861.

The cover, inspired by the research topic, was designed by Svetlana Tsogoeva, who conceived an idea of visualizating SARS-CoV-2 viruses and the new quinoline-morpholine hybrid compound, which proves to have a pronounced anti-SARS-CoV-2 activity. This simple design concept spurs on further efforts of the team to study the potential mechanistic mode of drug-mediated interference with the regulatory levels of viral replication, which is a relatively complex task.

What other topics are you working on at the moment?

Tsogoeva group: We are developing environmentally friendly synthetic methods toward new antiviral, anticancer and antimalarial compounds through the application of organocatalysts in one-pot and multistep domino reactions by using conventional reagents and also visible light. Beside this research, we are also working on the development of new PROTAC-based antiviral drug candidates.

Marschall group: We are studying the regulatory importance of protein kinases and their specific phosphorylation activities in the replication of the human pathogenic viruses, as manifested by viral intracellular transport processes, virus-host protein interactions, and various signaling pathways. Specifically, our investigations are focused on the antiviral potential of protein kinase inhibitors, now also including new PROTACs synthesized by the Tsogoeva group. These drugs could be exploited as a future antiviral targeting strategy.

Tsogoeva and co-workers at Friedrich-Alexander University of Erlangen-Nürnberg. The image depicts a new anti-SARS-CoV-2 compound in front of SARS-CoV-2 viruses